Plasmodium vivax and the related simian malarial parasite P. knowlesi use the DuffT blood group antigen as a receptor to invade human erythrocytes and region II of the parasite ligands for binding to this erythrocyte receptor. Here, we identify the peptide within the Duffy blood group antigen of human and rhesus erythrocytes to which the P. vivax and P. knowlesi ligands bind. Peptides from the NH2-terminal extracellular region of the Duffy antigen were tested for their ability to block the binding of erythrocytes to transfected Cos cells expressing on their surface region II of the Duffy-binding ligands. The binding site on the human Duffy antigen used by both the P. vivax and P. knowlesi ligands maps to a 35-amino acid region. A 34-amino acid peptide from the equivalent region of the rhesus Duffy antigen blocked the binding of P. vivax to human erythrocytes, although the P. vivax ligand expressed on Cos cells does not bind rhesus erythrocytes. The binding of the rhesus peptide, but not the rhesus erythrocyte, to the P. vivax ligand was explained by interference of carbohydrate with the binding process. Rhesus erythrocytes, treated with N-glycanase, bound specifically to P. vivax region II. Thus, the interaction of P. vivax ligand with human and rhesus erythrocytes appears to be mediated by a peptide-peptide interaction. Glycosylation of the rhesus Duffy antigen appears to block binding of the P. vivax ligand to rhesus erythrocytes.
I
nvasion of erythrocytes by Plasmodium merozoites is a multistep process that requires a series of specific molecular interactions between the invading merozoite and the target erythrocyte. P. vivax and the related simian malarial parasite, P. knowlesi, require interaction with the erythrocyte chemokine receptor, also known as the Duffy blood group antigen, to invade human erythrocytes (1) (2) (3) (4) (5) . Duffy-negative human erythrocytes, which lack the Duffy blood group antigen, are completely resistant to invasion by these parasites. Although P. knowlesi is absolutely dependent on the Duffy blood group antigen for invasion of human erythrocytes, P. knowlesi can efficiently invade rhesus erythrocytes by Duffy antigen-independent pathways (4). The erythrocyte receptors for P. knowlesi involved in these Duffy antigenindependent invasion pathways are not known.
The P. vivax and P. knowlesi ligands that bind to the Duffy blood group antigen contain a cysteine-rich domain that occurs in a superfamily of Plasmodium proteins that serve as host-binding ligands (6) . These include ligands that bind erythrocytes during invasion (7, 8) , as well as ligands that mediate binding of P. falciparum-infected erythrocytes to the endothelium (6, 9, 10) . This cysteine-rich domain, referred to as region II, is found in the Duffy-binding proteins of P. vivax and P. knowlesi (the ti gene), in other erythrocytebinding proteins of P. knowlesi (the [3 and y genes), and in the P. falciparum glycophorin A-binding protein EBA-175 (11) . When expressed in Cos cells, region II in the Duffybinding ligands of P. vivax and P. knowlesi binds human Duffy-positive erythrocytes with the same specificity as the protein from which it derives (7) .
In this paper, we identify the epitope in the Duffy blood group antigen that blocks the binding of Duffy-positive human erythrocytes to P. vivax region II that is expressed on the surface of Cos cells. Sequence analysis suggests that the human and rhesus Duffy antigens contain multiple transmembrane stretches with an ~64-amino acid hydrophilic region at the NH2 terminus that is extracellular (12) . Here, we demonstrate that a 35-amino acid peptide from this extracellular portion of the human Duffy blood group antigen blocks the binding ofDuffy-positive erythrocytes to region II of the Duffy-binding proteins of P. vivax and P. knowlesi. We find that the same region of the rhesus Duffy antigen also blocks binding of P. vivax region II to Duffy-positive human erythrocytes, although rhesus erythrocytes do not bind to P. vivax region II. Rhesus erythrocytes, however, can bind P. vivax region II after treatment with N-glycanase, which removes N-linked sugars, indicating that carbohydrates block the receptor on rhesus erythrocytes for P. viva,~c. These studies suggest that the P. vivax ligand can bind the peptide backbones of both the human and rhesus Duffy antigens.
Materials and Methods
Recombinant Plasmids for Surface Expression its Cos7 Cells. The plasmid constructs used to express region II of the P. vivax Dullybinding protein (pHVDP,22), the P. knowlesi Dully-binding protein (pHKADP,22), the P. knowlesi [3 protein (pHKBDR22) , and P. falciparum EBA-175 (EBA-175 RII) on the Cos cell surface have been described previously (7, 8) . Each of these constructs contains DNA sequences encoding region II of the parasite ligands fused with the signal sequence and transmembrane segment of herpes simplex virus glycoprotein D (HSV gD). The fusion proteins are targeted to the Cos cell surface by the signal sequence of HSV gD and are anchored to the surface by the transmembrane segment. These expression plasmids contain a SV40 origin of replication that allows replication in Cos7 cells, as well as a Rous sarcoma virus long terminal repeat that serves as a promoter for expression in Cos7 cells (13) .
Cell Culture and Tra,4~ection of Cos7 Cells. Cos7 cells (CRL 1651; American Type Culture Collection, Rockville, MD) were cultured in DMEM with 10% heat-inactivated FCS (both from GIBCO BP, L, Gaithersburg, MD) in a humidified CO2 (5%) incubator at 37~ Fresh monolayers of Cos7 cells were transfected in 3.5-cm-diameter wells with 5 txg ofplasmid DNA by the calcium phosphate precipitation method, as described earlier (7) . Cells were washed three times in PBS 12-16 h after transfection. Transfection efficiencies were determined by inmmnofluorescence assays 48-60 h after transfection, as described earlier (7) . Ascites containing the n~b DL6 (kindly provided by Drs. Gary Cohen and Roselyn Eisenberg, University of Pennsylvania, Philadelphia, PA) that reacts against amino acids 272-279 of the mature HSV gD protein were used as the primary antibody in the inmmnofluorescence assays as described earlier (13) .
Erythrocyte-binding Assays. Cos7 cells were transfected in 3.5-cm-diam wells and used for erythrocyte-binding assays 40-60 h after transfection, as described earlier (7) . Briefly, 100/xl of a 10% erythrocyte suspension was added to 0.9 ml of media in wells containing transfected cells. The plates were swirled to nfix the erythrocytes well, and the erythrocytes were allowed to settle tbr 2 h at 37~ Nonadherent erythrocytes were removed by washing the Cos7 cells three times with PBS, and the number oftransfected Cos7 cells with rosettes of erythrocytes was scored in 20 fields at a magnification of 40 using an inverted microscope.
To study the ability of peptides froln the Duffy antigen to inhibit erythrocyte binding, transfected Cos cells were preincubated for 1 h in a 5% CO 2 incubator at 37~ in 0.9 ml of complete DMEM with 10% FCS containing different concentrations (0-100 ixM) of peptides. Human or rhesus erythrocytes (100 txl) at a hematocrit of 10% were added to wells containing different concentrations of the peptides and were allowed to bind for 2 h at 37~ in a 5% CO 2 incubator. Nonadherent erythrocytes were removed by washing the Cos7 cells three times with PBS, and the number of rosettes was scored in 20 fields viewed at a magnification of 40() using an inverted nficroscope. Inhibition curves were drawn for three independent experiments and used to determine concentrations for 50% inhibition.
To study the ability of the chemokine MGSA (melanoma growth-stimulating activity) in inhibiting binding, erythrocytes were preincubated in media containing different concentrations of MGSA (0-1,000 nM) for 1 h at room temperature before they were used in erythrocyte-binding assays, as described earlier (7).
Erythrocytes and Pretreatments witll Enzymes. Blood was collected in 10% citrate phosphate dextrose (Baxter, Deerfield, IL) and stored at 4~ for up to 4 wk. Standard blood banking methods using two antisera (anti-Fya and anti-Fyb) were used to determine the Duffy phenotypes. Duffy-positive erythrocytes used in the binding assays had the Fy(a+b +) phenotype. Erythrocytes were washed three times in RPMI 1640 (GIBCO BP, L) and resuspended to a hematocrit of 10% in RPM[ 1640 for use in the erythrocyte-binding assays. Washed human and rhesus erythrocytes were treated with neuraminidase, as described earlier (14) . Human, rhesus, and squirrel monkey erythrocytes were deglycosylated with the N-glycanase peptide-N-glycosidase F from Flavobacterium me, ingosepticum (Oxford Glycosystems, Oxford, U.K.). Washed erythrocytes (10(I ~1) were incubated with mixing for 1 h at 37~ in 500 I*1 of PBS containing 10 U of N-glycanase and reaction buffer supplied by the manufacturer. The erythrocytes were washed extensively in PBS to remove the enzyme and stop the deglycosylation.
Pepticle Synthesis. Peptides were synthesized using an automated synthesizer, as described earlier (15) . Mass spectrophotometric and analytical reverse-phase HPLC analyses and amino acid composition were performed to confirm the purity and sequence of the synthetic peptides. In some cases, protein sequence analysis was also performed to check the sequence of the peptides.
Results and Discussion
Region II, the 5' cysteine-rich region of the P. vivax Duffy antigen-binding protein, has been shown to possess erythrocyte-binding properties (7) . Transfected Cos cells expressing P. vivax region II on the cell surface bind Duff-ypositive, but not Duffy-negative, human erythrocytes (7). Here, we have used the Cos cell-binding assay to identify the binding site on the human Duffy antigen that is used in this interaction. A 35-amino acid peptide (HPEP35) from the NH2-terminal extracellular domain of the human i)uffT antigen ( Fig. 1 a) was tested for its ability to inhibit binding of P. vivax region II to human erythrocytes in the Cos cellbinding assay. HPEP35 was chosen because it is recognized by anti-Fy6 (Chaudhuri, A., unpublished data), an mAb to the human Dully antigen that can block erythrocyte invasion by P. vivax in vitro (16) . To test the ability of HPEP35 to inhibit binding of human erythrocytes to P. vivax region II, Cos cell-binding assays were performed in the presence of increasing concentrations ((i)-100 b~M) of HPEP35. Fig. 2 shows the inhibition curve from one such experiment. HPEP35 inhibits the binding of Duffy-positive human erythrocytes to Cos cells expressing P. vivax region II with 50% inhibition at a concentration of 2.9 -+ /.4 txM ( Table 1) . Three smaller peptides from the 35-anfino acid region of HPEP35 were also tested in the inhibition assays (Fig. 1 b) . The smaller peptides (HPEP13, HPEP22, and HPEP3850) had no effect on the binding of human erythrocytes to re- 
*Average concentrations (-+ SD) for the peptides HPEP35 (Fig. 1 b) and RHPEP34 (Fig. 1 a) at which 50%} inhibition of binding is achieved are shown. Inhibition curves from two to three independent experiments were used to determine the average concentrations at which 50% inhibition is achieved. The highest concentration at which the peptides were tested was 100 t~M. For cases where the average concentrations for 5{)% inhibition is reported as >100 p~M, the inhibition was <5% at the highest peptide concentration used (100 IxM). Numbers in brackets (No. of studies) show the number of independent experiments used for the determination of the 50% inhibition concentrations.
fect on the binding of human erythrocytes to region II of EBA-175 or the binding of rhesus erythrocytes to region II of the P. knowlesi [3 protein at concentrations up to 100 btM ( Table 1) . The amino acid differences between the human and rhesus Duffy antigens in the 35-amino acid region that has been identified as the binding site are shown in Fig. 1 a. Compared with the human Duffy antigen, eight amino acid substitutions and a single amino acid deletion are evident in the rhesus sequence in this region (17) . To determine whether the corresponding 34-amino acid region of the rhesus Duffy antigen (RHPEP34) serves as the binding site for the P. knowlesi Duffy antigen-binding protein, the ability of RHPEP34 to inhibit erythrocyte binding in Cos cell assays was tested (Table 1 B) . RHPEP34 inhibits binding of rhesus as well as human erythrocytes to region II of the P. knowlesi Duffy-binding protein, indicating that RHPEP34 indeed serves as the binding site on the rhesus Duffy antigen for the P. knowlesi ligand. As a test for speci- One possible reason for this anomalous result with the synthetic peptide is that carbohydrates on the rhesus, but not the human, Duffy blood group antigen may block access of the parasite ligand to the peptide backbone of the receptor molecule. It has been demonstrated that the human Duffy blood group antigen has asparagine-linked glycosylation (18, 19) . Presumably, the rhesus Duffy antigen also has asparagine-linked glycosylation, since it contains the same amino acid sequence signals NXS/T as the human sequence (17) . To determine whether glycosylation of the rhesus Duffy blood group antigen influences binding, we studied the binding of normal and N-glycanase-treated rhesus erythrocytes to P. vivax region II. Whereas normal Rhesus N-glycanase >1 IxM *Normal and N--glycanase-treated rhesus erythrocytes were preincubated with different concentrations (0, 0.1, 1, 10, 100, and 1,000 nM) of the chemokine MGSA (melanoma growth~timulating activity) and used in binding assays with transfected Cos cells expressing P. vivax region II. Numbers represent concentrations at which 50% inhibition of binding was achieved. Two separate experiments were performed with P. vivax region II and N-glycanase-treated rhesus erythrocytes.
rhesus erythrocytes do not bind P. vivax region II, N-glycanase-treated rhesus erythrocytes bind the P. vivax ligand ( Table 2) . This indicates that, despite the differences in amino acid sequences, P. vivax can bind the peptide backbones of both the human and rhesus Duffy antigens. This explains why P, HPEP34, a peptide derived from the rhesus Duffy antigen, inhibits the binding of human erythrocytes to P. vivax region II.
Erythrocytes from a new world monkey, the squirrel monkey (Saimiri sciureus), do not bind the P. vivax Duffybinding protein (5), although they express the Duffy blood group antigen (16, 17) . We found that the squirrel monkey erythrocytes fail to bind to Cos cells expressing P. vivax region II, but do bind to Cos cells expressing the P. knowlesi Duffy binding protein (oL gene) region II (7) . N-glycanasetreated squirrel monkey erythrocytes, like rhesus erythrocytes, bind to Cos cells expressing P. vivax region II ( Table 2 ), indicating that carbohydrates on the Duffy blood group antigen of squirrel monkey erythrocytes also block its binding to the P. vivax Duffy-binding protein.
It can be argued that enzymatic treatment with N-glycanase reduces the negative surface charge density on erythrocytes and leads to nonspecific binding interactions. Another possibility that must be considered is that N-glycanase treatment may create a novel binding epitope independent of the Duffy blood group antigen. To test these possibilities, the following experiments were performed. Since sialic acid residues are the most important source of negative charge on the erythrocyte surface, neuraminidase-treated rhesus erythrocytes were tested for binding to P. vivax region II. Neuraminidase-treated rhesus erythrocytes did not bind P. vivax region II (Table 2 ). In the same experiment, neuraminidase-treated human erythrocytes did not bind region II of EBA-175, which requires sialic acid for binding, indicating that sialic acid was removed from the erythrocytes. Reduction of negative charge on the surface cannot, therefore, account for the binding of N-glycanase-treated rhesus erythrocytes to P. vivax region II. It was also found that N-glycanase-treated, Duffy-negative human erythrocytes do not bind P. vivax region II (Table 2 ). This rules out the possibility that N-glycanase treatment may create a novel epitope that binds P. vivax region II.
We have previously shown that the chemokine, MGSA, binds the Duffy blood group antigen and can be used to inhibit the binding ofP. vivax region II to Duff-y-positive human erythrocytes (3, 7) . MGSA also binds the rhesus Duffy antigen (Horuk, R., unpublished data). Indeed, MGSA inhibits the binding of rhesus erythrocytes to Cos cells expressing region II of the P. knowlesi Duffy-binding ligand (the (x gene; Table 3 ). To confirm that P. vivax region II binds the peptide backbone of the deglycosylated rhesus Duffy blood group antigen, we tested whether MGSA could inhibit the binding of N-glycanase-treated rhesus erythrocytes to P. vivax region II. MGSA inhibits the binding of N-glycanase--treated rhesus erythrocytes to region II of the P. vivax Duffy antigen-b, inding protein, with 50% inhibition at nanomolar concentrations ( Table 3) . Inhibition of erythrocyte binding indicates that MGSA and P. vivax region II bind the same molecule on N-glycanase-treated rhesus erythrocytes, namely the deglycosylated rhesus Duffy antigen. Chemokine and the P. vivax Duffy-binding protein, however, do not recognize the same epitope because the 35 met from the human Duffy antigen does not block binding of chemokines to human erythrocytes (Horuk, P,., unpublished data).
One puzzle is why P. vivax infects squirrel monkeys, although squirrel monkey erythrocytes do not bind P. vivax Duffy-binding protein (5) and also do not bind to Cos cells expressing P. vivax region II (this study). Squirrel monkey erythrocytes do contain the reticulocyte receptor to which the P. vivax reticulocyte-binding proteins bind (20) . Binding to the reticulocyte receptors is responsible for the preferential invasion ofreticulocytes by P. vivax (20) . These interactions are not, however, sufficient for invasion. For example, Duffy-negative human erythrocytes that carry the reticulocyte receptor are not invaded by P. vivax. We can speculate that the Duffy blood group antigen on squirrel monkey erythrocytes, despite not being ideal for binding because of carbohydrate modifications, still function in invasion. The erythrocyte-binding assays used may not be sensitive enough to detect this weaker interaction. How does one then explain the refractoriness of rhesus erythrocytes to invasion by P. vivax when P. vivax region II binds N-glycanase-treated rhesus erythrocytes? Rhesus erythrocytes are known to lack the reticulocyte receptor (20) for the P. vivax reticulocyte-binding proteins. It is possible that, like the Duffy antigen, the reticulocyte receptor is also absolutely required for invasion. Their absence on rhesus erythrocytes may be the reason for their refractoriness to P. vivax.
Differences exist between the nature of the receptorbinding specificities for region II of P. falciparum EBA-175 and of the P. vivax Duffy-binding ligand. Whereas P. falciparum EBA-175 requires both sialic acid and the peptide backbone of glycophorin A (8, 14) , the P. vivax Duffybinding ligand requires only the peptide backbone of the Duffy blood group antigen. Both tryptic fragments of glycophorin A containing amino acids 1-64 and the 35-amino acid synthetic peptide from the extracellular domain of the Duffy antigen inhibit binding of erythrocytes to their respective ligands with 50% inhibition at concentrations of ",5 I,~M (reference 8, and this paper). Thus, peptides derived from the Duffy antigen (in the absence of any carbohydrates) appear to effectively inhibit erythrocyte binding by the P. vivax ligand. Furthermore, rhesus erythrocytes can bind P. vivax region II after treatment with N-glycanase. We conclude that the receptor-ligand interactions that mediate erythrocyte invasion differ in the protein to which they bind and in the requirement for carbohydrate. The receptor for P. falciparum EBA-175 consists of both carbohydrate and the peptide backbone of glycophorin A; the P. vivax Duffy-binding ligand interacts only with the peptide backbone of the receptor molecule.
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